About us

The first and only topical pain and wound management product for animals

Our quest is to enter the human market with our
leading pain mitigation and accelerated wound
healing platform technology.

Offering a patient focused solution to advance the standard of care for chronic and acute wounds, the technology has been developed as a topical “spray and stay” formulation providing several benefits when applied including pain relief, reduced bleeding and anti-bacterial activity.

Future near-term opportunities for the human proprietary product Medi-Solfen® include the treatment of traumatic wounds caused by surgical procedures, and mass trauma situations such as accidents, military conflict and natural disasters.

We are a life science development company
focused on mitigating pain and minimising suffering
from wounds, in humans

Team

Our mission

End unnecessary wound pain and reduce wound-related morbidity and mortality.

Medi-Solfen® has significantly reduced
commercialisation risks

Our story

Medical Ethics Pty Ltd pioneered the development, launch, and commercialization of the first and only globally available topical pain and wound management product for animals, setting a new benchmark for animal welfare.

Tri-Solfen® was the first product developed from the Medical Ethics Solfen-Tech® platform and has been successfully commercialized for use in animals. This patented platform technology represents a transformational approach to mitigating pain and suffering associated with wounds in animals.

The Solfen-Tech® technology provides essential wound care for surgical procedures in sheep, pigs, cattle, equine, and companion animals. These painful procedures include dehorning, tail docking, castration, and fly-strike prevention.

The group has successfully registered Tri-Solfen® in Australia, New Zealand, United Kingdom and Portugal with registrations pending in several other countries including the European Union and the United States.

Medi-Solfen Pty Ltd, a carve-out from Medical Ethics Pty Ltd, continues to build on this legacy, specifically addressing wound care needs in humans.